麦味养肺汤通过p53信号通路抑制细胞衰老改善小鼠肺纤维化OA

This study aimed to investigate the therapeutic effect of Maiwei Yangfei Decoction(MWYF)on pulmonary fibrosis and its underlying mechanisms.Seventy-two C57BL/6J mice were randomly divided into a blank group,a model group,a low-dose MWYF group,a medium-dose MWYF group,a high-dose MWYF group,and a pirfenidone group.A pulmonary fibrosis model was established by intratracheal instillation of bleomycin.The blank group and the model group were administered double-distilled water daily,while the MWYF groups received corresponding concentrations of MWYF,and the positive control group was given pirfenidone.The severity of pulmonary fibrosis was assessed through Micro-CT scans,histopathological staining of lung tissues,and the expression of collagen Ⅰ and collagen Ⅲ.Network pharmacology combined with transcriptomics analysis was used to explore the anti-fibrotic mechanism of MWYF,which was further validated through in vivo experiments.The results showed that MWYF reduced pulmonary fibrotic lesions,improved inflammation and fibrosis scores,and downregulated the protein expression of collagen Ⅰ and collagen Ⅲ.Network pharmacology and transcriptomics suggested that the anti-fibrotic effect of MWYF was associated with cellular senescence and the p53 signaling pathway.In vivo experiments demonstrated that MWYF significantly reduced senescence-associated β-galactosidase(SA-β-Gal)activity in lung tissues,downregulated the expression of key senescence-related proteins p53,p21,and p16,and decreased cellular senescence,with the high-dose group showing the most pronounced effects.Collectively,these findings demonstrated that MWYF attenuated bleomycin-induced pulmonary fibrosis in mice,likely by suppressing cellular senescence via modulation of the p53 signaling pathway.